With the clinical success of CD19 CAR-T cell therapy on B-ALL for young and pediatric patients, CAR-T cells targeting these AML-associated antigens have been developed and have shown increasingly higher anti-tumor efficacy compared to mAb therapy. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.